{
    "nctId": "NCT01150513",
    "briefTitle": "Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer",
    "officialTitle": "Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 320,
    "primaryOutcomeMeasure": "Disease Free Survival (DFS) of 3 years",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Triple-negative breast cancer\n* Older than 18 years old\n* Have tumor resection surgery\n* Sufficient organ function (marrow, heart, liver)\n\nExclusion Criteria:\n\n* Other malignancy\n* Other serious disease( marrow, heart, liver)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}